## nature portfolio

Corresponding author(s):	Sjors Scheres
Last updated by author(s)	: 01/26/2024

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

$\sim$				
V1	- ~	+ 1	ct	-c
ر.	d	L.	IStI	เนอ

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
	$\boxtimes$	The exact sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement
$\boxtimes$		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
$\boxtimes$		The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.
$\boxtimes$		A description of all covariates tested
$\boxtimes$		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
$\boxtimes$		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
$\boxtimes$		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
$\boxtimes$		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
$\boxtimes$		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
$\boxtimes$		Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated
		Our web collection on statistics for biologists contains articles on many of the points above.

## Software and code

Policy information about availability of computer code

Data collection

We used publicly available data from EMPIAR, plus a new data set on Aca2:RNA that will be published in an independent paper elsewhere.

Data analysis

RELION is open-source (GPLv2 license) and can be downloaded from https://github.com/3dem. We used RELION version 5.0-beta-1. Parts of the code of Blush were written in pytorch (we used version 2.0.1). Code used in the training of the Blush denoiser is available from https://github.com/dkimanius/blush-training.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

## Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

A list of EMDB entries used for training, plus manually curated masks can be downloaded from https://zenodo.org/records/10553452. We used publicly available

number 11918).	om the EMPIAR o	data base (accession numbers 10330, 10180 and 11720). The Aca2:RNA data set as been uploaded to EMPIAR (accession		
Human rese	arch parti	cipants		
Policy information	about <u>studies i</u>	nvolving human research participants and Sex and Gender in Research.		
Reporting on sex and gender		N/A		
Population characteristics		N/A		
Recruitment		N/A		
Ethics oversight		N/A		
Note that full informa	ation on the appr	oval of the study protocol must also be provided in the manuscript.		
Field-spe	ecific re	porting		
Please select the o	ne below that i	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
Life sciences	E	sehavioural & social sciences Ecological, evolutionary & environmental sciences		
For a reference copy of	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life scier	nces sti	udy design		
All studies must dis	sclose on these	points even when the disclosure is negative.		
Sample size	Cryo-EM data set sizes were determined by the publicly available data sets from EMPIAR, or by the number of acquired micrographs for the Ste2 and Aca2:RNA data sets.			
Data exclusions	We used previously published data sets in their entirety. For the Aca2:RNA data set, we performed 3D classification as indicated in figure 6 to select the particles giving rise to the final map.			
Replication	No replication experiments were performed, as noise on the outcome of the computational analysis was not considered to be affecting the conclusions.			
Randomization	For each data set, two random half-sets were employed for resolution estimation. Randomisation was performed using a random number generator.			
Blinding	Blinding is not performed in cryo-EM analysis, because knowledge of the target by the experimentalist is not expected to affect the outcome of the reconstruction algorithm.			
We require informati	ion from authors ted is relevant to	Decific materials, systems and methods  about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.  ystems  Methods		
n/a Involved in th	<u> </u>	n/a Involved in the study		

ChIP-seq

Flow cytometry

MRI-based neuroimaging

Antibodies

Clinical data

Eukaryotic cell lines

Palaeontology and archaeology
Animals and other organisms

Dual use research of concern